Table 5.
Adverse Events (all adverse events suggestive of potential immune-related etiology were listed).
| Event | Patients, n (%) | Median cycle of onset | ||
|---|---|---|---|---|
| Any grade | G1−2 | G3−4 | ||
| Neutropenia | 30 (57.7) | 26 (50.0) | 4 (7.7) | 2 |
| Lymphocytopenia | 24 (46.2) | 18 (34.6) | 6 (11.5) | 2 |
| Anemia | 28 (53.8) | 27 (51.9) | 1 (1.9) | 2 |
| Thrombocytopenia | 9 (17.3) | 9 (17.3) | 0 | 4 |
| Asthenia | 24 (46.2) | 23 (44.3) | 1 (1.9) | 3 |
| Liver toxicitya | 21 (40.4) | 20 (38.5) | 1 (1.9) | 2 |
| Nausea | 17 (32.7) | 16 (30.8) | 1 (1.9) | 2 |
| Vomiting | 17 (32.7) | 17 (32.7) | 0 | 2 |
| Rash cutaneous | 12 (23.1) | 12 (23.1) | 0 | 2 |
| Diarrhea | 10 (19.2) | 10 (19.2) | 0 | 3 |
| Peripheral neuropathy | 10 (19.2) | 8 (15.4) | 2 (3.8) | 2 |
| Stomatitis | 10 (19.2) | 10 (19.2) | 0 | 2 |
| Hepatitis | 6 (11.5) | 5 (9.6) | 1 (1.9) | 3 |
| Thyroiditis | 6 (11.5) | 6 (11.5) | 0 | 3 |
| Pneumonia | 5 (9.6) | 5 (9.6) | 0 | 2 |
| Fever | 5 (9.6) | 5 (9.6) | 0 | 3 |
| Onychopathy | 2 (3.8) | 2 (3.8) | 0 | 3 |
aTransaminase increasing.